Skip to content
Sign in
Artwork for DarshanTalks Podcast
ScienceLife SciencesEducationHow ToSociety & CultureDocumentary

DarshanTalks Podcast

Darshan Kulkarni

Welcome to DarshanTalks!  152254 

We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there! 

Powered By The Kulkarni Law Firm -  Helping regulators see your business the way you do. 

We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career. 


152254

Play
Open in
  • 21 episodes
  • weekly
  • Avg 10 min
  • English

Support the show

Goes straight to the publisher. podnod takes nothing.

Episodes 21

NewestOldestLongest
All1Unplayed1In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • April 9 · 2 min

    Safe or Just "Not Dirty"? The Regulatory Gamble of Compounded Drugs

    Send us Fan Mail In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven science." If you are a patient, a provider, or a legal professional in the life sciences space, you need to understand the four pillars of FDA approval—and why some of the most popular drugs on the market today are legally allowed to skip the hardest parts Support the show www.kulkarnilawfirm.com

    • Transcript
Showing 21–21 of 21 episodes